Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) Tops Q1 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus

April 30, 2019 7:12 AM EDT

Incyte (NASDAQ: INCY) reported Q1 EPS of $0.62, $0.22 better than the analyst estimate of $0.40. Revenue for the quarter came in at $498 million versus the consensus estimate of $489.03 million.

Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019Jakafi® (ruxolitinib) revenues of $376 million in Q1 2019 (+20%... More